Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Project Management

- PMLiVE

Does disruptive thinking leave you feeling threatened?

What it takes to change healthcare

- PMLiVE

Open minds for open innovation

When it comes to problem-solving, getting an outsider’s perspective can really add value. Addressing an issue from a different angle or injecting new expertise ultimately leads to a more robust...

- PMLiVE

Biotech: it’s a people business

Nancy Hunter is the Marketing Director at a cutting-edge pharmaceutical company. Here she explains how a sharp focus on patients’ needs is driving a new operating model for marketing first-in-class...

Blue Latitude Health

Is the pharma business model ready for precision medicine?

Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Blue Latitude Health

The NHS and ABPI at 70: inching closer to the triple win

The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...

- PMLiVE

Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

A rapid round up of news from pharma, biotech and healthcare

- PMLiVE

KYNE bolsters digital offering

Medit will take the helm of KYNE’s digital strategy

- PMLiVE

Morning brief: New biotech launched, Merck and Moderna expand collaboration and more

A rapid round up of pharma, biotech and healthcare news

- PMLiVE

Disruptive technologies set to stabilise soaring drug prices

AI and blockchain could accelerate the drug development process, says report

Pharma’s isolated islands of innovation

With service design and technology often failing the patient, why perspective on improving outcomes need to change

- PMLiVE

BenevolentAI raises $115m to fund drug development

Its technology could cut the early stage drug discovery process by four years, says the company

Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies

Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links